{
  "ticker": "ELVN",
  "company_name": "Enliven Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05650879",
      "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification",
      "start_date": "2023-03-20",
      "completion_date": "2026-07",
      "enrollment": 0,
      "sponsor": "Enliven Therapeutics"
    },
    {
      "nct_id": "NCT06328738",
      "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer",
      "start_date": "2024-05-30",
      "completion_date": "2028-07",
      "enrollment": 0,
      "sponsor": "Enliven Therapeutics"
    },
    {
      "nct_id": "NCT05304377",
      "title": "A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml",
      "start_date": "2022-05-22",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Enliven Therapeutics"
    },
    {
      "nct_id": "NCT06787144",
      "title": "ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "CML (Chronic Myelogenous Leukemia), Chronic Phase CML",
      "start_date": "2025-01-23",
      "completion_date": "2028-01",
      "enrollment": 0,
      "sponsor": "Enliven Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 4,
    "by_phase": {
      "PHASE1": 4
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "RECRUITING": 2
    },
    "active_trials": 4,
    "completed_trials": 0,
    "conditions": [
      "CML (Chronic Myelogenous Leukemia), Chronic Phase CML",
      "Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml",
      "HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification",
      "HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:08.125029",
    "search_query": "Enliven Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Enliven+Therapeutics,+Inc."
  }
}